Skip to main content
Medtronic agrees to acquire Contego for $380 million
Image for illustrative purposes only. Not a real photo.

Medtronic agrees to acquire Contego for $380 million

By

Key points

  • Medtronic (NYSE:MDT) agreed to acquire privately held Contego Medical in a transaction valued at $380 million, with additional potential payments.
  • The deal adds the FDA-approved Neuroguard IEP Direct System for carotid artery treatment and Excipio devices for removing blood clots from peripheral vessels.
  • Medtronic expects the acquisition to have a minimal dilutive effect on adjusted earnings per share in fiscal 2027 and 2028, with neutral to accretive effects thereafter.

Medtronic (NYSE:MDT) agreed to acquire Contego Medical in a transaction valued at $380 million, expanding its portfolio of vascular treatment devices.

The acquisition builds on an exclusive U.S. distribution agreement announced in January 2025 and adds products targeting carotid artery disease and peripheral vascular conditions.

The U.S. Food and Drug Administration approved the Neuroguard IEP Direct System on November 4, 2026, while Excipio devices expand the portfolio into peripheral thrombectomy, which removes blood clots from blood vessels.

In the 146-patient pivotal PERFORMANCE III study, researchers reported no strokes, myocardial infarctions, neurological deaths or cranial nerve injuries within 30 days, although one unrelated cardiac death resulted in a 0.7% major adverse event rate.

Medtronic expects the acquisition to close in its fiscal third quarter, subject to customary closing conditions, and forecasts minimal adjusted earnings per share dilution in fiscal 2027 and 2028, followed by neutral to accretive results.

The transaction builds on Medtronic's January 2025 exclusive U.S. distribution agreement with Contego, under which Medtronic became the sole U.S. distributor for its commercially available carotid and peripheral vascular products.


Frequently asked questions